J Ints Bio

J Ints Bio (Korean: 제이인츠바이오) is a South Korean biopharmaceutical company headquartered in Seoul. It positions itself at the intersection of artificial intelligence and drug discovery, describing its mission as the "Convergence of Science & Business." The company is best known for an oncology-focused pipeline and for its JIN-NOVA AI drug-discovery platform, which it says is built on optimized bio-supercomputing infrastructure and a cloud-based drug-development environment used to continuously generate drug candidates. J Ints Bio's disclosed pipeline centers on small-molecule and related oncology assets. JIN-A02 is being developed for non-small cell lung cancer (NSCLC). JIN-A04, also aimed at non-small cell lung cancer, is noted on the company's website as having been licensed from Yuhan Corporation (Yuhan Yanghaeng). JIN-001 is being developed for solid tumors and glioblastoma, and the company states it is being co-developed with MD Anderson. These programs place J Ints Bio in the competitive field of targeted oncology, where resistance to existing therapies is a major clinical challenge. The company presents itself as a science-and-business hybrid, combining AI-enabled discovery with clinical development. Its website highlights management-system certifications rather than consumer products: ISO 9001:2015 for quality management, ISO 37001:2016 for anti-bribery management, and ISO 37301:2021 for compliance management. These certifications are used to signal reliable quality, ethical transparency and sustainable compliance practices to partners and investors. J Ints Bio maintains a Korean-language corporate site with an English-language option, and it publishes notices, news and financial information. Recent news items on its site include selection for the Ministry of SMEs and Startups' "Scale-up TIPS" program to advance AI drug development, and coverage of its JIN-A02 clinical program in the context of overcoming resistance in lung cancer. The company also publishes shareholder-related notices such as new-share issuance announcements. Because J Ints Bio is a privately held, relatively young biotech, public information about its founding date, founders, ownership structure and financials is limited. Its identity as a commercial entity is clear: it is a drug-development company with named pipeline assets, a named AI platform, and a corporate web presence. It should not be confused with any non-commercial namesake.

J Ints Bio (Korean: 제이인츠바이오) is a South Korean biopharmaceutical company based in Seoul. It operates as an AI-enabled drug-discovery and development company, presenting itself under the tagline "Convergence of Science & Business." The company's public identity is built around two pillars: a clinical-stage oncology pipeline and the JIN-NOVA AI drug-discovery platform. The company's website describes JIN-NOVA as an innovation in AI drug development. According to the company, J Ints Bio optimizes bio-supercomputing infrastructure and builds a cloud-based drug-development environment to continuously generate drug candidates. This positions the company within the broader trend of computational and AI-assisted drug discovery, where large-scale data and simulation are used to identify and prioritize therapeutic molecules. J Ints Bio's disclosed pipeline includes JIN-A02 for non-small cell lung cancer, JIN-A04 (also referred to as YH42946) for non-small cell lung cancer, and JIN-001 for solid tumors and glioblastoma. The company states that JIN-A04 was in-licensed from Yuhan Corporation (Yuhan Yanghaeng), a well-known South Korean pharmaceutical company, and that JIN-001 is being co-developed with MD Anderson. These relationships indicate that J Ints Bio operates within a network of Korean and international research and development partners. The company emphasizes management systems and certifications. Its website lists ISO 9001:2015 for quality management, ISO 37001:2016 for anti-bribery management, and ISO 37301:2021 for compliance management. These certifications are presented as evidence of reliable quality, ethical transparency and sustainable compliance, which are relevant signals for a biotech seeking partnerships and investment. J Ints Bio maintains a Korean-language corporate website with an English option. The site includes sections for company introduction, CEO greeting, company history, organizational chart, corporate philosophy, partnerships, sustainability management, business areas, pipeline, notices and news, financial information, and location. The presence of a financial information section and shareholder notices such as new-share issuance announcements suggests the company communicates with investors, though its listing status is not established by the available evidence. Recent news highlighted on the company's site includes its selection for the Ministry of SMEs and Startups' "Scale-up TIPS" program, which supports technology development, specifically to advance AI drug development. Other news items discuss the clinical context for JIN-A02, including commentary from Professor Cho Byoung-chul of Severance Hospital on overcoming resistance in lung cancer treatment and the promise of fourth-generation EGFR targeted therapies. These items illustrate the company's focus on oncology, particularly lung cancer, and its efforts to position its pipeline within the evolving standard of care. Because J Ints Bio is a relatively young, privately held biotech, detailed public information about its founding, founders, ownership and financial history is limited. The available evidence establishes its location in Seoul, its pipeline and platform, its certifications, and its recent news activity, but does not provide a full corporate history with dated milestones. The company remains active as of the latest dated news item on its website.

• News coverage features Professor Cho Byoung-chul discussing JIN-A02 and fourth-generation EGFR targeted therapy for lung cancer.

• Company publishes notice of new share issuance.

• J Ints Bio selected for the Ministry of SMEs and Startups' 'Scale-up TIPS' program to advance AI drug development.

AI-driven oncology drug discovery company combining bio-supercomputing and cloud-based drug development with a clinical-stage pipeline.

• JIN-A02

  Drug candidate for non-small cell lung cancer.

• JIN-A04 (YH42946)

  Drug candidate for non-small cell lung cancer, in-licensed from Yuhan Corporation.

• JIN-001

  Drug candidate for solid tumors and glioblastoma, co-developed with MD Anderson.

• JIN-NOVA

  AI drug-discovery platform using bio-supercomputing infrastructure and a cloud-based drug-development environment.

1. 1(주)제이인츠바이오 official websitejintsbio.com
2. 2J Ints Bio (South Korea) on Wikidatawikidata.org